Siagran

Acute treatment of migraine attacks w/ or w/o aura.

Adult 50 or 100 mg as single dose. May give 2nd dose of up to 100 mg after 2 hr if headache returns or patient has partial response to initial dose. Max: 300 mg daily. Mild to moderate hepatic impairment Max: 50 mg.

May be taken with or without food: Swallow whole w/ water, do not chew/crush.

Hypersensitivity. Ischemic heart disease, Prinzmetal's angina, angina pectoris, MI, silent myocardial ischemia, coronary artery vasospasm, peripheral vascular disease, ischemic bowel disease; cerebrovascular syndromes including strokes, transient ischemic attacks; uncontrolled HTN; Wolff-Parkinson-White syndrome or arrhythmias associated w/ other cardiac accessory conduction pathway disorders; hemiplegic or basilar migraine. Concomitant use w/ MAOIs, especially isoenzyme A therapy; ergot alkaloids & 5-HT₁ agonist w/in 24 hr treatment. Severe hepatic impairment.

Anaphylactic, anaphylactoid & hypersensitivity reactions, particularly patients w/ known hypersensitivity to sulphonamides. Not to be used for prophylaxis. Excessive use of drugs (≥10 days/mth) for acute migraine attacks. Patients w/ controlled HTN & BP; history of epilepsy or other conditions predisposing to seizures. Exclude other potentially serious neurologic conditions before initiation of therapy in patients not previously diagnosed w/ migraine attacks & w/ history of migraine presenting w/ atypical symptoms. Consider CV evaluation prior to initiation of therapy in patients w/ multiple CV risk factors eg, postmenopausal women, men >40 yr, patients w/ risk factors (eg, HTN, hypercholesterolemia, obesity, diabetes, smoking, or history of CAD) who have not previously received therapy w/ 5-HT₁ receptor agonist; periodic interval CV evaluation in patients w/ intermittent long-term use of 5-HT₁ agonist. Concomitant use w/ SSRIs (eg, fluoxetine, fluvoxamine, paroxetine, sertraline) or SNRIs (eg, duloxetine). May impair ability to drive & operate machines. Renal impairment. Mild to moderate hepatic impairment. Pregnancy. Avoid breastfeeding for 12 hr after receiving treatment. Childn & adolescents <18 yr. Elderly >65 yr.

Malaise or fatigue, nausea or vomiting, dizziness or vertigo, tingling, nasal discomfort, atypical sensation & sensations of pain, heaviness, pressure or tightness. Burning sensation, numbness, phonophobia, photophobia; chest pain, HTN, hypotension, palpitation, syncope; diarrhea; myalgia; allergic rhinitis, dyspnea, sinusitis, upper resp tract inflammation; ear, nose, throat haemorrhage, hearing loss, external otitis, nasal inflammation, noise sensitivity, tinnitus.

Decreased clearance & increased t_½ & blood conc w/ MAO-A inhibitors eg, moclobemide. Prolonged vasospastic reactions & vasoconstrictor effects w/ ergot alkaloids. Serotonin syndrome w/ SSRIs (eg, fluoxetine, fluvoxamine, paroxetine, sertraline) or SNRIs (eg, duloxetine). Increased risk of vasospastic reactions w/ 5-HT₁ agonist.

Antimigraine Preparations

N02CC01 - sumatriptan ; Belongs to the class of selective serotonin (5HT1) agonists preparations. Used to relieve migraine.

D